These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39039770)

  • 1. Seroprevalence of SARS-CoV-2 in pediatric hematology-oncology patients.
    Phan V; Richards T; Kang K; Sheridan M; Levorson R; deFilippi C; Yang E
    Pediatr Blood Cancer; 2024 Oct; 71(10):e31212. PubMed ID: 39039770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study.
    Szanyi J; Price DJ; Carville KS; Batty M; Yallop S; Nicholson S; Karapanagiotidis T; Rowe S; Sullivan S; Menon V; West D; Manoharan L; Copsey E; Majumdar SS; Sutton B; Williamson DA; McVernon J
    Commun Dis Intell (2018); 2024 Aug; 48():. PubMed ID: 39165016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study.
    Anderson AR; Strouse JJ; Manwani D; Brandow AM; Vichinsky E; Campbell A; Leavey PJ; Nero A; Ibrahim IF; Field JJ; Baer A; Soto-Calderon H; Vincent L; Zhao Y; Santos JJS; Hensley SE; Mortier N; Lanzkron S; Neuberg D; Abrams CS
    Blood Adv; 2024 Sep; 8(17):4549-4553. PubMed ID: 38991137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system.
    Chervo TC; Elkin EP; Nugent JR; Valice E; Amsden LB; Ergas IJ; Munneke JR; Flores M; Saelee GN; Hsiao CA; Schapiro JM; Quesenberry CP; Corley DA; Habel LA; Kushi LH; Skarbinski J
    PLoS One; 2024; 19(6):e0303303. PubMed ID: 38900738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents.
    Messiah SE; Talebi Y; Swartz MD; Sabharwal R; Han H; Bergqvist E; Kohl HW; Valerio-Shewmaker M; DeSantis SM; Yaseen A; Kelder SH; Ross J; Padilla LN; Gonzalez MO; Wu L; Lakey D; Shuford JA; Pont SJ; Boerwinkle E
    Pediatr Res; 2024 Jul; 96(2):525-534. PubMed ID: 37875728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.
    Liu WD; Lin MS; Sun HY; Shih MC; Chuang YC; Huang YS; Lin KY; Li GC; Wu PY; Chen LY; Liu WC; Su YC; He PC; Chen YT; Lin CY; Cheng YC; Yao Y; Yeh YC; Liu CC; Pan MY; Luo YZ; Chang HY; Wang JT; Sheng WH; Hsieh SM; Chang SY; Hung CC
    J Microbiol Immunol Infect; 2024 Aug; 57(4):554-563. PubMed ID: 38429206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
    Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
    Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal study on SARS-CoV-2 seroconversion, reinfection and neutralisation spanning several variant waves and vaccination campaigns, Heinsberg, Germany, April 2020 to November 2022.
    Schulte B; Richter E; Büning A; Baum M; Breuer A; Zorn J; König J; Geiger M; Eschbach-Bludau M; Heuser J; Zölzer D; Korencak M; Hollstein R; Beins E; Emmert D; Aldabbagh S; Eis-Hübinger AM; Streeck H
    Euro Surveill; 2024 Jun; 29(26):. PubMed ID: 38940003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to COVID-19 vaccination in patients on cancer therapy: Analysis in a SARS-CoV-2-naïve population.
    Cavic G; Almonte AA; Hicks SM; Neeman T; Wang JW; Brew S; Choi PY; Cockburn I; Gardiner EE; Yip D; Fahrer AM; Kanjanapan Y
    Asia Pac J Clin Oncol; 2024 Jun; 20(3):379-385. PubMed ID: 38221764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age dependent discrepancy between SARS-CoV-2 anti-nucleoprotein antibody and anti-RBD spike protein antibody in children reflects vaccine coverage.
    Fujii Y; Ishigaki H; Miyairi I; Niizeki N; Nagura O; Yamashita K; Maekawa M; Furuhashi K
    J Infect Chemother; 2024 Jul; 30(7):646-650. PubMed ID: 38309499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.
    van Dam P; Huizing M; Roelant E; Hotterbeekx A; De Winter FHR; Kumar-Singh S; Moons P; Amajoud Z; Vulsteke C; Croes L; Janssens A; Berneman Z; Prenen H; Meuris L; Vanden Berghe W; Smits E; Peeters M
    Eur J Cancer; 2021 May; 148():328-339. PubMed ID: 33773276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.
    Tunheim G; Fossum E; Robertson AH; Rø GØI; Chopra A; Vaage JT; Vikse EL; Kran AB; Magnus P; Trogstad L; Mjaaland S; Hungnes O; Lund-Johansen F
    BMC Infect Dis; 2024 Aug; 24(1):841. PubMed ID: 39164637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023.
    Kinoshita R; Miyamoto S; Sakuraba S; Sugihara J; Suzuki M; Suzuki T; Yoneoka D
    Emerg Infect Dis; 2024 Jun; 30(6):1267-1270. PubMed ID: 38782366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies.
    Wüsthoff LEC; Lund-Johansen F; Henriksen K; Wildendahl G; Jacobsen JA; Gomes L; Anjum HS; Barlinn R; Kran AB; Munthe LA; Vaage JT
    Harm Reduct J; 2024 Jun; 21(1):120. PubMed ID: 38890611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.